Results 21 to 30 of about 73,703 (332)
Measurement, modeling and QALYs [PDF]
F1000Research, 2020 Over the past 30 years, a mainstay of health technology assessment has been the creation of modeled incremental cost-per-quality adjusted life year (QALY) claims. These are intended to inform resource allocation decisions. Unfortunately, the reliance on the construction of QALYs from generic utility scales is misplaced.
Paul C. Langley, Stephen P. McKenna
openaire +2 more sources
Евразийский Кардиологический Журнал, 2021 The study aims to estimate the MitraClip system’s cost-effectiveness compared with optimal medical therapy in adult patients with inoperable mitral regurgitation and assess its impact on the budget of the Russian Federation health system.Materials and ...
E. G. Fedina +3 more
doaj +1 more source
Фармацевтичний журнал, 2022 Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease that causes the blood vessels in the lungs to thicken and narrow, forcing the heart to pump blood through the lungs at high pressure. In recent years, a significant number
I. S. Datsenko, A. V. Kabachna
doaj +1 more source
Фармацевтичний журнал, 2023 Over the past decades, health policy makers have focused on early diagnosis to introduce targeted and innovative treatments. Early diagnosis of pulmonary arterial hypertension (PAH) is associated with improved long-term survival, so screening high-risk ...
I. S. Datsenko
doaj +1 more source
A cost utility and cost effectiveness analysis of different oral antiviral medications in patients with HBeAg-Negative chronic hepatitis B in Iran: an economic microsimulation decision model [PDF]
, 2016 Background: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB).
Alavian, Seyed Moayed +9 more
core +1 more source
Научно-практическая ревматология, 2010 Heavy economic expenses for treatment with genetic engineering biologicals (GEB) in patients with rheumatoid arthritis (RA) determine what strategies are most optimal in terms of both their clinical efficiency and economic constituent should be sought ...
Dmitry Vladimirovich Goryachev +2 more
doaj +1 more source
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
Expert Review of Vaccines, 2023 Introduction Studies on economic evaluations of the 13-valent pneumococcal conjugate vaccine (PCV13) have been increasing over the last decade. No systematic reviews have synthesized the evidence of economic evaluations of the PCV13.
Yuanze Du +11 more
doaj +1 more source
Towards a transparent, credible, evidence-based decision-making process of new drug listing on the Hong Kong Hospital Authority Drug Formulary: challenges and suggestions [PDF]
, 2017 The aim of this article is to describe the process, evaluation criteria, and possible outcomes of decision-making for new drugs listed in the Hong Kong Hospital Authority Drug Formulary in comparison to the health technology assessment (HTA) policy ...
Cheung, Bernard M.Y. +2 more
core +2 more sources
Фармакоэкономика, 2019 The aim of the review was to analyze the availability of insulin therapy and the ways to improve it in countries with the largest number of patients with diabetes. It was also aimed to assess the medical, social and economic importance of insulin therapy
S. V. Ponomarenko
doaj +1 more source
Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand [PDF]
, 2015 Objectives. Haemophilia A is a congenital disorder of coagulation that mainly affects males and causes a considerable use of resources, especially when hemophilic patients are treated with prophylaxis.
BOCCIA, Antonio +4 more
core +2 more sources